To the best of our knowledge, this is the first study to evaluate whether the combined cardiac biomarkers approach incorporating hs-Tnl and BNP can provide incremental benefit in risk prediction of MACE in stable CAD patients with and without T2DM. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.